Kiluk Paulina, Baran Anna, Świderska Magdalena, Maciaszek Magdalena, Flisiak Iwona
Department of Dermatology and Venereology, Medical University of Bialystok, Bialystok, Poland.
Department of Physiology, Medical University of Bialystok, Bialystok, Poland.
J Dermatolog Treat. 2020 Aug;31(5):524-530. doi: 10.1080/09546634.2019.1606887. Epub 2019 May 15.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a well- known risk factor of atherosclerotic vascular diseases which are common comorbidities in psoriasis. The aim of this study was to evaluate serum Lp-PLA2 level in psoriatic patients and elucidate possible associations with disease activity, metabolic or inflammatory parameters and systemic treatment. We enrolled 33 patients with active plaque-type psoriasis and 11 healthy controls. Blood samples were collected before and after 3 months of systemic treatment with acitretin or methotrexate. Serum Lp-PLA2 level were evaluated by enzyme-linked immunosorbent assay. Serum Lp-PLA2 level in patients with psoriasis did not statistically differ comparing to the control group ( = .2). However, in patients with severe psoriasis Lp-PLA2 was significantly higher than in the controls before and after treatment ( = .03, = .01, respectively). The lipase did not correlate with BMI ( = .22); however, a statistical significance was noted between psoriatics with obesity compared to the controls ( = .03). No significant effect of systemic treatment combined ( = .5) nor separately with acitretin ( = .5) or methotrexate ( = .1) on the Lp-PLA2 level was found, despite clinical improvement. Lp-PLA2 assay might be helpful in assessment of the risk of cardiometabolic comorbidities development especially in patients with severe psoriasis and obesity.
脂蛋白相关磷脂酶A2（Lp-PLA2）是动脉粥样硬化性血管疾病的一个众所周知的危险因素，而动脉粥样硬化性血管疾病是银屑病常见的合并症。本研究的目的是评估银屑病患者的血清Lp-PLA2水平，并阐明其与疾病活动、代谢或炎症参数以及全身治疗之间可能存在的关联。我们招募了33例活动性斑块型银屑病患者和11名健康对照者。在使用阿维A或甲氨蝶呤进行全身治疗3个月之前和之后采集血样。通过酶联免疫吸附测定法评估血清Lp-PLA2水平。银屑病患者的血清Lp-PLA2水平与对照组相比无统计学差异（P = 0.2）。然而，在重度银屑病患者中，治疗前后Lp-PLA2均显著高于对照组（分别为P = 0.03，P = 0.01）。该脂肪酶与体重指数无相关性（P = 0.22）；然而，肥胖的银屑病患者与对照组相比有统计学意义（P = 0.03）。尽管有临床改善，但未发现联合全身治疗（P = 0.5）以及单独使用阿维A（P = 0.5）或甲氨蝶呤（P = 0.1）对Lp-PLA2水平有显著影响。Lp-PLA2检测可能有助于评估尤其是重度银屑病和肥胖患者发生心脏代谢合并症的风险。
